The decrease in Bristol-Myers Squibb's stock price is directly attributed to the market's reaction to their Q1 earnings report. Typically, a negative response to earnings reports can lead to a short-term decline in stock price, reflecting investor disappointment or concern over the company's financial health and future prospects.